Table 1 Patient demographics of the analyzed study population.
From: Microbiota-based markers predictive of development of Clostridioides difficile infection
Total number of patients | 945 |
|---|---|
Age (median [IQR]) | 70 [61–79] |
Male gender (%) | 557 (58.9) |
Myocardial infarction (%) | 78 (8.25) |
Congestive heart failure (%) | 134 (14.2) |
Peripheral vascular disease (%) | 143 (15.1) |
Cerebrovascular disease (%) | 81 (8.57) |
COPD (%) | 144 (15.2) |
Connective tissue disease (%) | 53 (5.61) |
Peptic ulcer disease (%) | 50 (5.29) |
Diabetes mellitus (%) | 268 (28.4) |
Moderate to severe chronic kidney disease (%) | 127 (13.4) |
Hemiplegia (%) | 16 (1.69) |
Leukemia (%) | 55 (5.82) |
Malignant lymphoma (%) | 68 (7.20) |
Solid tumor (%) | 208 (22.0) |
Liver disease (%) | 88 (9.31) |
AIDS (%) | 10 (1.06) |
Intestinal obstruction (%) | 5 (0.53) |
Inflammatory bowel disease (%) | 14 (1.48) |
Other non-specified comorbidities (%) | 538 (56.9) |
Has history of CDI (%) | 14 (1.48) |
Developed CDI within study period (%) | 14 (1.48) |
Developed AAD within study period (%) | 64 (6.77) |
Country of origin | |
|---|---|
France (%) | 210 (22.2) |
Germany (%) | 145 (15.3) |
Greece (%) | 85 (8.99) |
The Netherlands (%) | 14 (1.48) |
Romania (%) | 184 (19.5) |
Spain (%) | 307 (32.2) |
Antibiotic treatment received from D1 to D5 | |
|---|---|
Penicillin + beta-lactamase inhibitor (PBL, %) | 194 (20.5) |
Other beta-lactam antibiotics (OBL, %) | 133 (14.1) |
Fluoroquinolones (FQN, %) | 63 (6.67) |
Combination therapy and other (%) | 347 (36.7) |
Patients without a D6 sample (%) | 208 (22.0) |
